CSF biomarkers and their role in Alzheimer’s disease
Pages: 52-53
Samantha Yeoh1
1Contributed by Samantha Yeoh, Digital Content Specialist, Roche Diagnostics Asia Pacific.
E-mail: hong-yew.lim@roche.com
Abstract
Amid the continued ageing of the global population, Alzheimer’s disease is a serious and rapidly growing public health concern. The Asia Pacific region alone is estimated to have over 23 million cases today, and that figure is projected to be more than 70 million cases by 2050 [1]. While much attention is currently on a new therapeutic intervention recently approved by the FDA, clinical lab diagnostics will also be essential for helping to manage this growing crisis.
